While new science continues to evolve the development of drugs and cures, the scientific principals we use to evaluate the drugs is arguably obsolete. Host Dr. Bruce Bloom is joined in this segment by Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, and Dr. Scott Gottlieb, a practicing physician and resident fellow at the American Enterprise Institute (AEI). Listen in to learn how clinical trial models might be changed to better evaluate the success of new drugs that target subsets of the population with certain cancers, and expedite translatable cures.